+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vector Manufacturing Markets and Technologies Through 2030- Product Image
Viral Vector Manufacturing Markets and Technologies Through 2030- Product Image
New

Viral Vector Manufacturing Markets and Technologies Through 2030

  • PDF Icon

    Report

  • 202 Pages
  • September 2025
  • Region: Global
  • BCC Research
  • ID: 6177916
Description Jump to:
The global market for viral vector manufacturing is expected to grow from $6.3 billion in 2025 and is projected to reach $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 24.6% during the forecast period of 2025 to 2030.

The use of viral vectors in gene therapy is transforming healthcare, with an increase in the demand for Good Manufacturing Practice (GMP) grade materials. The process of bringing a viral vector from concept to clinic requires extensive optimization and characterization, affecting every stage from cell culture to purification and concentration. Variations in vector titer during the upstream phase may result from the specific transgene being packaged or from constitutive or “leaky” tissue-specific promoters, which can induce unintended protein expression, and, in turn, impact vector yield and quality. Therefore, increasing the production of GMP-grade materials is crucial to meet the growing demand for clinical applications.

Market Dynamics and Growth Factors

Viral-based vectors are at the core of cell and gene therapy, enabling researchers and clinicians to develop powerful drug platforms. Over the past five years, regulatory approvals for viral vector-based drugs have surged, ranging from cancer therapies to treatments for monogenic diseases. The three dominant vector strategies are adenoviruses, adeno-associated viruses, and lentiviruses, which have led to preclinical and clinical breakthroughs over the last two decades.

Market drivers include the increasing incidence of chronic diseases, rising approvals of vector-based therapies, and growing demand for viral vector production. Market restraints include the process and cost barriers in viral vector development, roadblocks with viral vectors, and the high cost linked with viral vector production.

Report Scope

This report analyzes viral vector manufacturing market trends using 2024 data, 2025 estimates, market projections and compound annual growth rates (CAGRs) for the forecast period of 2025-2030. The report discusses viral vector manufacturing’s current and future market potential and covers regulatory scenarios, drivers, restraints, and opportunities.

The report segments the market by type, application and disease. Types include adenoviral vectors (AdVs), adeno-associated viral vectors (AAVs), lentiviral vectors (LVs), retroviral vectors (RVs), and other viral vectors. Applications consist of multivalent and multipathogen. Diseases are segmented into human and veterinary. Human diseases are further segmented into HIV, tuberculosis, cancer, influenza, malaria, hepatitis, and others. Veterinary diseases are further segmented into avian influenza, Marek’s disease, infectious bronchitis, and PPR disease.

The market has been segmented into the regions of North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The markets of individual countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India, are analyzed.

The goals of the report are to:

  • Analyze types of viral vectors.
  • Calculate the size of the global market size, with forecasts through 2030.
  • Identify market constraints and drivers.
  • Assess company’s market shares, competitiveness, and industry structure.
  • Identify potential long-term impacts on the viral vector manufacturing market.

Report Includes

  • Overview and analysis of the global viral vector manufacturing markets and technologies
  • Analyses of the global market trends, with historic sales revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
  • Estimates of the market’s size and revenue prospects, accompanied by a market share analysis based on type, application, disease segment and region
  • Facts and figures pertaining to market dynamics, technological advancements, regulations, prospects, and the impacts of macroeconomic variables
  • Insights derived from Porter’s Five Forces model and global value chain analysis
  • An assessment of the viral vaccine pipeline products, clinical trials, competitive scenario and R&D activities
  • An analysis of patents, emerging trends and new developments in the industry
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, and M&A activity
  • Profiles of the leading companies

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion
Chapter 2 Market Overview
  • Overview
  • Macroeconomic Factors
  • Impact of U.S. Tariffs on the Pharmaceutical Industry
  • Healthcare Expenditures
  • Impact of Global Economic Growth (GDP) on Pharma Sector
  • Direct Economic Impact
  • Indirect Economic Impact
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Potential for New Entrants to Market
  • Threat of Substitutes
  • Competitiveness in the Industry
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Chronic Diseases
  • Approvals of Vector-Based Therapies
  • Demand for Viral Vector Production
  • Market Restraints
  • Process and Cost Barriers in Viral Vector Development
  • Viral Vector Roadblocks
  • High Cost Linked with Viral Vector Production
  • Market Opportunities
  • Emerging Viral-Based Therapies
  • Digitalization in Viral Vector Production
Chapter 4 Regulatory Landscape
  • Overview
  • United States
  • Europe
  • Japan
Chapter 5 Emerging Technologies and Pipeline Analysis
  • Overview
  • Automation
  • Next-Generation Production Systems
  • Genome Editing
  • Pipeline Analysis
  • Takeaways
  • Patent Analysis
  • Takeaways
Chapter 6 Market Segmentation Analysis
  • Segmentation Breakdown
  • Global Market for Viral Vector Manufacturing by Type
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Adeno-Associated Viral Vectors
  • Retroviral Vectors (RVs)
  • Other Viral Vectors
  • Global Viral Vector Manufacturing Market, by Application
  • Multivalent Viral Vector Vaccines
  • Multipathogen Viral Vector Vaccines
  • Global Market for Viral Vector Manufacturing, by Disease
  • Veterinary Diseases
  • Human Diseases
  • Geographic Breakdown
  • Global Market for Viral Vector Manufacturing, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
Chapter 7 Competitive Intelligence
  • Market Share Analysis
  • Market Share Analysis
  • Recent Developments
Chapter 8 Sustainability in the Viral Vector Manufacturing Industry: An ESG Perspective
  • Introduction to ESG
  • Sustainability in the Viral Vector Manufacturing Industry
  • ESG Perspective
  • Environmental Impact
  • Waste Management
  • Social Impact
  • Governance Impact
  • ESG Risk Ratings
  • Conclusion
Chapter 9 Appendix
  • Methodology
  • Abbreviations
  • Sources
  • Company Profiles
  • ABL Inc.
  • Catalent Inc.
  • Charles River Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Diosynth Biotechnologies
  • Lonza
  • Merck Kgaa
  • Novartis Ag
  • Oxford Biomedica Plc.
  • Probio
  • Revvity
  • Sanofi
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Emerging Players in the Viral Vector Manufacturing Market
List of Tables
Summary Table: Global Market for Viral Vector Manufacturing, by Region, Through 2030
Table 1: Health Expenditures as a Percentage of GDP
Table 2: Approved Viral Vector-Based Gene Therapies, 2021-2025
Table 3: Recent Regulatory Updates for Viral-Based Gene Therapies, 2025
Table 4: Clinical Trial Studies on Viral Vector Manufacturing, 2024-2025
Table 5: Patents Related to Viral Vector Manufacturing, 2025
Table 6: Global Market for Viral Vector Manufacturing, by Type, Through 2030
Table 7: Global Market for LV Manufacturing, by Region, Through 2030
Table 8: Global Market for AdV Manufacturing, by Region, Through 2030
Table 9: Global Market for AAV Manufacturing, by Region, Through 2030
Table 10: Approved CAR-T Products and Associated RVs, 2017-2024
Table 11: Global Market for RV Manufacturing, by Region, Through 2030
Table 12: Global Market for Other Viral Vector Manufacturing, by Region, Through 2030
Table 13: Global Market for Viral Vector Manufacturing, by Application, Through 2030
Table 14: Global Market for Multivalent Viral Vector Vaccine Manufacturing, by Region, Through 2030
Table 15: Global Market for Multipathogen Viral Vector Vaccine Manufacturing, by Region, Through 2030
Table 16: Global Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 17: Licensed Viral-Vectored Veterinary Vaccines
Table 18: Global Market for Viral Vectors in Veterinary Diseases, by Disease, Through 2030
Table 19: Global Market for Viral Vectors in Veterinary Diseases, by Region, Through 2030
Table 20: Licensed Viral and Bacterial Vaccines for Use in Humans
Table 21: HIV Global Epidemic, by Age Group, 2023
Table 22: Global Market for Viral Vectors in Human Diseases, by Disease, Through 2030
Table 23: Global Market for Viral Vectors in Human Diseases, by Region, Through 2030
Table 24: Globally Approved Gene Therapies, 2022-2025
Table 25: Global Market for Viral Vector Manufacturing, by Region, Through 2030
Table 26: North American Market for Viral Vector Manufacturing, by Type, Through 2030
Table 27: North American Market for Viral Vector Manufacturing, by Application, Through 2030
Table 28: North American Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 29: North American Market for Viral Vector Manufacturing, by Country, Through 2030
Table 30: FDA-Approved AAVs in Gene Therapy, 2017-2024
Table 31: U.S. Market for Viral Vector Manufacturing, by Type, Through 2030
Table 32: U.S. Market for Viral Vector Manufacturing, by Application, Through 2030
Table 33: U.S. Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 34: Canadian Market for Viral Vector Manufacturing, by Type, Through 2030
Table 35: Canadian Market for Viral Vector Manufacturing, by Application, Through 2030
Table 36: Canadian Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 37: Influenza Vaccination Coverage in Mexico, 2020-2023
Table 38: Mexican Market for Viral Vector Manufacturing, by Type, Through 2030
Table 39: Mexican Market for Viral Vector Manufacturing, by Application, Through 2030
Table 40: Mexican Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 41: European Market for Viral Vector Manufacturing, by Type, Through 2030
Table 42: European Market for Viral Vector Manufacturing, by Application, Through 2030
Table 43: European Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 44: European Market for Viral Vector Manufacturing, by Country, Through 2030
Table 45: German Market for Viral Vector Manufacturing, by Type, Through 2030
Table 46: German Market for Viral Vector Manufacturing, by Application, Through 2030
Table 47: German Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 48: U.K. Market for Viral Vector Manufacturing, by Type, Through 2030
Table 49: U.K. Market for Viral Vector Manufacturing, by Application, Through 2030
Table 50: U.K. Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 51: French Market for Viral Vector Manufacturing, by Type, Through 2030
Table 52: French Market for Viral Vector Manufacturing, by Application, Through 2030
Table 53: French Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 54: Italian Market for Viral Vector Manufacturing, by Type, Through 2030
Table 55: Italian Market for Viral Vector Manufacturing, by Application, Through 2030
Table 56: Italian Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 57: Spanish Market for Viral Vector Manufacturing, by Type, Through 2030
Table 58: Spanish Market for Viral Vector Manufacturing, by Application, Through 2030
Table 59: Spanish Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 60: Rest of Europe Market for Viral Vector Manufacturing, by Type, Through 2030
Table 61: Rest of Europe Market for Viral Vector Manufacturing, by Application, Through 2030
Table 62: Rest of Europe Viral Vector Manufacturing Market, by Disease Type, Through 2030
Table 63: Approved Gene Therapies in Asia-Pacific Region, 2021-2023
Table 64: Asia-Pacific Market for Viral Vector Manufacturing, by Type, Through 2030
Table 65: Asia-Pacific Market for Viral Vector Manufacturing, by Application, Through 2030
Table 66: Asia-Pacific Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 67: Asia-Pacific Market for Viral Vector Manufacturing, by Country, Through 2030
Table 68: Chinese Market for Viral Vector Manufacturing, by Type, Through 2030
Table 69: Chinese Market for Viral Vector Manufacturing, by Application, Through 2030
Table 70: Chinese Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 71: Japanese Market for Viral Vector Manufacturing, by Type, Through 2030
Table 72: Japanese Market for Viral Vector Manufacturing, by Application, Through 2030
Table 73: Japanese Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 74: Indian Market for Viral Vector Manufacturing, by Type, Through 2030
Table 75: Indian Market for Viral Vector Manufacturing, by Application, Through 2030
Table 76: Indian Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 77: South Korean Market for Viral Vector Manufacturing, by Type, Through 2030
Table 78: South Korean Market for Viral Vector Manufacturing, by Application, Through 2030
Table 79: South Korean Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 80: Australian Market for Viral Vector Manufacturing, by Type, Through 2030
Table 81: Australian Market for Viral Vector Manufacturing, by Application, Through 2030
Table 82: Australian Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 83: Rest of Asia-Pacific Market for Viral Vector Manufacturing, by Type, Through 2030
Table 84: Rest of Asia-Pacific Market for Viral Vector Manufacturing, by Application, Through 2030
Table 85: Rest of Asia-Pacific Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 86: MEA Market for Viral Vector Manufacturing, by Type, Through 2030
Table 87: MEA Market for Viral Vector Manufacturing, by Application, Through 2030
Table 88: MEA Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 89: MEA Market for Viral Vector Manufacturing, by Sub-Region, Through 2030
Table 90: Middle East Market for Viral Vector Manufacturing, by Type, Through 2030
Table 91: Middle East Market for Viral Vector Manufacturing, by Application, Through 2030
Table 92: Middle East Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 93: African Market for Viral Vector Manufacturing, by Type, Through 2030
Table 94: African Market for Viral Vector Manufacturing, by Application, Through 2030
Table 95: African Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 96: South American Market for Viral Vector Manufacturing, by Type, Through 2030
Table 97: South American Market for Viral Vector Manufacturing, by Application, Through 2030
Table 98: South American Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 99: South American Market for Viral Vector Manufacturing, by Country, Through 2030
Table 100: Brazilian Market for Viral Vector Manufacturing, by Type, Through 2030
Table 101: Brazilian Market for Viral Vector Manufacturing, by Application, Through 2030
Table 102: Brazilian Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 103: Argentine Market for Viral Vector Manufacturing, by Type, Through 2030
Table 104: Argentine Market for Viral Vector Manufacturing, by Application, Through 2030
Table 105: Argentine Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 106: Rest of South America Market for Viral Vector Manufacturing, by Type, Through 2030
Table 107: Rest of South America Market for Viral Vector Manufacturing, by Application, Through 2030
Table 108: Rest of South America Market for Viral Vector Manufacturing, by Disease Type, Through 2030
Table 109: Recent Developments in the Viral Vector Manufacturing Industry, 2022-2025
Table 110: Focus Areas in ESG Metrics
Table 111: ESG Rankings for Leading Viral Vector Manufacturing Companies, 2025
Table 112: Abbreviations Used in this Report
Table 113: Report Sources
Table 114: ABL Inc.: Company Snapshot
Table 115: ABL Inc.: Product Portfolio
Table 116: ABL Inc.: News/Key Developments, 2024
Table 117: Catelent Inc: Company Snapshot
Table 118: Catalent Inc: Product Portfolio
Table 119: Catalent Inc: News/Key Developments, 2022-2023
Table 120: Charles River Laboratories: Company Snapshot
Table 121: Charles River Laboratories: Financial Performance, FY 2023 and 202
Table 122: Charles River Laboratories: Product Portfolio
Table 123: Charles River Laboratories: News/Key Developments, 2022-2024
Table 124: Danaher Corp.: Company Snapshot
Table 125: Danaher Corp.: Financial Performance, FY 2023 and 2024
Table 126: Danaher Corp.: Product Portfolio
Table 127: Danaher Corp.: News/Key Development, 2022-2023
Table 128: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 129: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 130: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 131: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2025
Table 132: Fujifilm Diosynth Biotechnologies: Company Snapshot
Table 133: Fujifilm Diosynth Biotechnologies: Product Portfolio
Table 134: Lonza: Company Snapshot
Table 135: Lonza: Financial Performance, FY 2023 and 2024
Table 136: Lonza: Product Portfolio
Table 137: Merck KGaA: Company Snapshot
Table 138: Merck KGaA: Financial Performance, FY 2023 and 2024
Table 139: Merck KGaA: Product Portfolio
Table 140: Merck KGaA: News/Key Developments, 2022-2024
Table 141: Novartis AG: Company Snapshot
Table 142: Novartis AG: Financial Performance, FY 2023 and 2024
Table 143: Novartis AG: Product Portfolio
Table 144: Novartis AG: News/Key Developments, 2025
Table 145: Oxford Biomedica PLC.: Company Snapshot
Table 146: Oxford Biomedica PLC.: Financial Performance, FY 2023 and 2024
Table 147: Oxford Biomedica PLC.: Product Portfolio
Table 148: Oxford Biomedica PLC.: News/Key Developments, 2023
Table 149: ProBio: Company Snapshot
Table 150: ProBio: Product Portfolio
Table 151: ProBio: News/Key Developments, 2024
Table 152: Revvity: Company Snapshot
Table 153: Revvity: Financial Performance, FY 2023 and 2024
Table 154: Revvity: Product Portfolio
Table 155: Sanofi: Company Snapshot
Table 156: Sanofi: Financial Performance, FY 2023 and 2024
Table 157: Sanofi: Product Portfolio
Table 158: Sanofi: News/Key Developments, 2022
Table 159: Takara Bio Inc.: Company Snapshot
Table 160: Takara Bio Inc.: Financial Performance, FY 2023 and 2024
Table 161: Takara Bio Inc.: Product Portfolio
Table 162: Takara Bio Inc.: News/Key Developments, 2023-2024
Table 163: Thermo Fisher Scientific Inc.: Company Snapshot
Table 164: Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 165: Thermo Fisher Scientific Inc.: Product Portfolio
Table 166: Thermo Fisher Scientific Inc.: News/Key Developments, 2022
Table 167: Emerging Players in the Viral Vector Manufacturing Market
List of Figures
Summary Figure: Global Market Shares for Viral Vector Manufacturing, by Region, 2024
Figure 1: Porter’s Five Forces Analysis of the Viral Vector Manufacturing Market
Figure 2: Market Dynamics Snapshot of Viral Vector Manufacturing
Figure 3: Distribution Share of the Most Frequent Cancer Types in Women*, 2022
Figure 4: Distribution Share of the Most Frequent Cancer Types in Men*, 2022
Figure 5: Estimated New Cancer Cases and Deaths in the U.S. in 2024
Figure 6: Global Market Shares for Viral Vector Manufacturing, by Therapy Type, 2024
Figure 7: Global Market Shares for LV Manufacturing, by Region, 2024
Figure 8: Global Market Shares for AdV Manufacturing, by Region, 2024
Figure 9: Global Market Shares for AAV Manufacturing, by Region, 2024
Figure 10: Global Market Shares for RV Manufacturing, by Region, 2024
Figure 11: Global Market Shares for Other Viral Vector Manufacturing, by Region, 2024
Figure 12: Global Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 13: Global Market Shares for Multivalent Viral Vector Vaccine Manufacturing, by Region, 2024
Figure 14: Global Market Shares for Multipathogen Viral Vector Vaccine Manufacturing, by Region, 2024
Figure 15: Global Market Shares for Viral Vector Manufacturing, by Disease, 2024
Figure 16: Global Market Shares for Viral Vectors in Veterinary Diseases, by Region, 2024
Figure 17: Global Market Shares for Viral Vectors in Human Diseases, by Region, 2024
Figure 18: Global Market Shares for Viral Vector Manufacturing, by Region, 2024
Figure 19: North American Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 20: North American Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 21: North American Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 22: North American Market Shares for Viral Vector Manufacturing, by Country, 2024
Figure 23: U.S. Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 24: U.S. Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 25: U.S. Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 26: Canadian Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 27: Canadian Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 28: Canadian Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 29: Mexican Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 30: Mexican Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 31: Mexican Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 32: European Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 33: European Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 34: European Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 35: European Market Shares for Viral Vector Manufacturing, by Country, 2024
Figure 36: German Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 37: German Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 38: German Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 39: U.K. Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 40: U.K. Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 41: U.K. Market Shares for Viral Vector Manufacturing, by Disease, 2024
Figure 42: French Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 43: French Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 44: French Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 45: Italian Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 46: Italian Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 47: Italian Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 48: Spanish Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 49: Spanish Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 50: Spanish Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 51: Rest of Europe Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 52: Rest of Europe Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 53: Rest of Europe Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 54: Asia-Pacific Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 55: Asia-Pacific Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 56: Asia-Pacific Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 57: Asia-Pacific Market Shares for Viral Vector Manufacturing, by Country, 2024
Figure 58: Chinese Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 59: Chinese Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 60: Chinese Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 61: Japanese Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 62: Japanese Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 63: Japanese Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 64: Indian Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 65: Indian Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 66: Indian Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 67: South Korean Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 68: South Korean Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 69: South Korean Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 70: Australian Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 71: Australian Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 72: Australian Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 73: Rest of Asia-Pacific Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 74: Rest of Asia-Pacific Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 75: Rest of Asia-Pacific Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 76: MEA Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 77: MEA Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 78: MEA Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 79: MEA Market Shares for Viral Vector Manufacturing, by Sub-Region, 2024
Figure 80: Middle East Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 81: Middle East Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 82: Middle East Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 83: African Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 84: African Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 85: African Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 86: South American Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 87: South American Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 88: South American Market Shares for American Viral Vector Manufacturing, by Disease Type, 2024
Figure 89: South American Market Shares for Viral Vector Manufacturing, by Country, 2024
Figure 90: Brazilian Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 91: Brazilian Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 92: Brazilian Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 93: Argentine Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 94: Argentine Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 95: Argentine Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 96: Rest of South America Market Shares for Viral Vector Manufacturing, by Type, 2024
Figure 97: Rest of South America Market Shares for Viral Vector Manufacturing, by Application, 2024
Figure 98: Rest of South America Market Shares for Viral Vector Manufacturing, by Disease Type, 2024
Figure 99: Global Market Shares for Viral Vector Manufacturing, by Company, 2024
Figure 100: Pillars of ESG
Figure 101: Advantages of ESG for Companies
Figure 102: Charles River Laboratories: Revenue Shares, by Business Unit, FY 2024
Figure 103: Charles River Laboratories: Revenue Shares, by Country/Region, FY 2024
Figure 104: Danaher Corp.: Revenue Shares, by Business Unit, FY 2024
Figure 105: Danaher Corp.: Revenue Shares, by Country/Region, FY 2024
Figure 106: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 107: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 108: Lonza: Revenue Shares, by Business Unit, FY 2024
Figure 109: Lonza: Revenue Shares, by Country/Region, FY 2024
Figure 110: Merck KGaA: Revenue Shares, by Business Unit, FY 2024
Figure 111: Merck KGaA: Revenue Shares, by Country/Region, FY 2024
Figure 112: Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 113: Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 114: Oxford Biomedica PLC.: Revenue Shares, by Business Unit, FY 2024
Figure 115: Oxford Biomedica PLC.: Revenue Shares, by Country/Region, FY 2024
Figure 116: Revvity: Revenue Shares, by Business Unit, FY 2024
Figure 117: Revvity: Revenue Shares, by Country/Region, FY 2024
Figure 118: Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 119: Takara Bio Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 120: Takara Bio Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 121: Thermo Fisher Scientific Inc.: Market Shares, by Business Unit, FY 2024
Figure 122: Thermo Fisher Scientific Inc.: Market Shares, by Country/Region, FY 2024

Companies Mentioned

  • ABL Inc.
  • Catalent Inc.
  • Charles River Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Diosynth Biotechnologies
  • Lonza
  • Merck Kgaa
  • Novartis Ag
  • Oxford Biomedica Plc.
  • Probio
  • Revvity
  • Sanofi
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages202
PublishedSeptember 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.8 Billion
Compound Annual Growth Rate24.6%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Viral Vector and Plasmid DNA: Technologies and Global Markets - Product Image

Viral Vector and Plasmid DNA: Technologies and Global Markets

  • Report
  • 128 Pages
  • Global
From
Viral Vector Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Viral Vector Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Viral Vector Production Market Size, Share & Trends Analysis Report By Type (Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others), By Indication, By Application, By Regional Outlook and Forecast, 2023 - 2030 - Product Image

Viral Vector Production Market Size, Share & Trends Analysis Report By Type (Adeno-Associated Viral Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, and Others), By Indication, By Application, By Regional Outlook and Forecast, 2023 - 2030

  • Report
  • Global
From
Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028 - Product Image

Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028

  • Report
  • 317 Pages
  • Global
From
Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2025-2032 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2025-2032

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.